Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 19, 2023 (3 years ago)

Nafcillin for Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Nafcillin for Injection, USP, 1 gram per vial, Rx only, Mfd. for SAGENT Pharmaceuticals, Schaumburg, IL 60195. NDC: 25021-139-10

Affected NDC 25021-0139-10

Compare with the code on your package — it is the most precise check available.

Drug: Nafcillin

Recalling firm
Sagent Pharmaceuticals Inc
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0762-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Nafcillin recalls

See all

Other recalls by Sagent Pharmaceuticals Inc

All 2023 recalls
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0554-2024
Class I · High risk

Docetaxel Injection

Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.

Ongoing Particulate / foreign matter Sagent Pharmaceuticals NDC 25021-254-08 D-0553-2024